Summary
Tobira Therapeutics Inc (Tobira), formerly Regado Biosciences, Inc, which develops and commercializes therapies for the treatment of to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, inflammation, fibrosis and HIV. Its pipeline products include Cenicriviroc (CVC) and Evogliptin (EVO). The company’s lead product candidate, cenicriviroc, is a proprietary immunomodulator which is used to treat diseases such as HIV-1, and others. Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 inhibitor which prevents the breakdown of incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The company seeks partnership for in-licensing and combination therapy development for the fibrosis, inflammation and HIV. Tobira is headquartered in San Francisco, California, the US.
Tobira Therapeutics Inc (TBRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Tobira Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 9
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Regado Biosciences Raises US$51 Million In Series E Financing 12
Regado Biosciences Raises US$6.8 Million In Venture Financing 14
Regado Biosciences Secures US$11.6 Million In Financing 15
Tobira Therapeutics Secures US$31 Million In Series B Round Of Financing 16
Tobira Therapeutics Secures US$4 Million In Venture Financing 18
Regado Biosciences Raises US$14.55 Million In Venture Financing 19
Merger 20
Regado Biosciences Merges with Tobira Therapeutics 20
Licensing Agreements 22
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 22
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 24
Equity Offering 26
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 26
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 27
Tobira Therapeutics Withdraws IPO 29
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 31
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 33
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 34
Debt Offering 36
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 36
Acquisition 38
Allergan Acquires Tobira Therapeutics in Tender Offer 38
Tobira Therapeutics Inc - Key Competitors 40
Key Employees 41
Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Tobira Therapeutics Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Tobira Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 9
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Regado Biosciences Raises US$51 Million In Series E Financing 12
Regado Biosciences Raises US$6.8 Million In Venture Financing 14
Regado Biosciences Secures US$11.6 Million In Financing 15
Tobira Therapeutics Secures US$31 Million In Series B Round Of Financing 16
Tobira Therapeutics Secures US$4 Million In Venture Financing 18
Regado Biosciences Raises US$14.55 Million In Venture Financing 19
Regado Biosciences Merges with Tobira Therapeutics 20
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 22
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 24
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 26
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 27
Tobira Therapeutics Withdraws IPO 29
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 31
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 33
Regado Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$43 Million 34
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 36
Allergan Acquires Tobira Therapeutics in Tender Offer 38
Tobira Therapeutics Inc, Key Competitors 40
Tobira Therapeutics Inc, Key Employees 41
List of Figures
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Tobira Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Tobira Therapeutics Inc, Medical Devices Deals, 2010 to YTD 2016 9
